Actively Recruiting
Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations
Led by University Hospital, Grenoble · Updated on 2026-04-15
240
Participants Needed
2
Research Sites
195 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Grenoble
Lead Sponsor
H
Hospices Civils de Lyon
Collaborating Sponsor
AI-Summary
What this Trial Is About
Although we know that these numbers are underestimated, Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that affects between 8 and 12% of adults. According to a 2020 WHO report, it is the third most common cause of mortality in developed countries. This disease is punctuated by exacerbations associated with an 8% mortality of hospitalized patients, increased to 24% when the patient is admitted to intensive care unit. Early detection and treatment of these exacerbations appears to be essential to improve patient survival. End-tidal carbon dioxide (EtCO2) is used to assess a patient's respiratory and hemodynamic status. Indeed, EtCO2 is a non-invasive measure that could allow the estimation of arterial carbon dioxide (PaCO2) without performing blood gases, an arterial blood sampling, classically at the radial artery. This study aimed to find an EtCO2 value which at the time of the initial management, would be predictive of a severe COPD exacerbation, as well as PaCO2.
CONDITIONS
Official Title
Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients presenting to the emergency department with acute dyspnea and a documented or reported history of COPD
- Male or female aged 18 years or older who agree to participate in the study
You will not qualify if you...
- Hypotension (systolic blood pressure below 90 mmHg or mean blood pressure below 65 mmHg)
- Patients previously included in the study during an earlier emergency department visit
- Patients already receiving invasive or non-invasive ventilation upon admission to the emergency department
- COPD exacerbation ruled out after medical and additional examinations
- Patients who are non-communicative, do not speak French, have impaired comprehension, or impaired consciousness
- Individuals legally protected under French public health code articles L1121-6 and L1121-8 (such as those deprived of liberty, under tutorship or curatorship)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
CHU Grenoble Alpes
Grenoble, Isère, France, 38000
Actively Recruiting
2
Hospices Civils de Lyon
Lyon, Rhône, France, 69000
Actively Recruiting
Research Team
N
Nicolas SEGOND, MD
CONTACT
P
Prudence MABIALA MAKELE, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here